Mirati’s KRAS Inhibitor Gains Edge On Efficacy, But Safety Trails Amgen’s Competing Drug
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.
You may also be interested in...
Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.